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 Introduction : People with chronic kidney disease (CKD) of stages 3-5 (creatinine clearance 
< 60 ml/min) represent 25-30% of  patients with type 2 diabetes  (T2DM), but the problem is 
underrecognized or neglected in clinical practice. However, most oral antidiabetic agents have 
limitations in case of renal impairment, either because they require a dose adjustment or 
because they are contraindicated for safety reasons. 
Area covered: An extensive literature search was performed to analyze the influence of renal 
impairment on the pharmacokinetics (PK) of glucose-lowering agents and the potential 
consequences for clinical practice. The following pharmacological classes will be considered : 
biguanides (metformin), sulfonylureas, meglitinides (glinides), alpha-glucosidase inhibitors, 
thiazolidinediones (glitazones),  dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose 
cotransporters 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, 
insulin and insulin analogues.  
Expert Opinion : Because of potential important PK interferences and for safety reasons, the 
pharmacological management of T2DM should be adjusted according to kidney function. In 
general, the daily dose should be reduced according to glomerular filtration rate (GFR) or 
even the drug is contraindicated in presence of more severe CKD. This is the case for 
metformin (risk of lactic acidosis) and for many sulfonylureas (risk of hypoglycemia). At 
present, however, the exact GFR cutoff for metformin use is controversial. New antidiabetic 
agents are better tolerated in case of CKD, although clinical experience remains quite limited 
for most of them. The dose of DPP-4 inhibitors should be reduced (except for linaglitpin) 




Key-words : Chronic kidney disease – Glomerular filtration rate – Glucose-lowering therapy  
– Pharmacokinetics – Oral antidiabetic agent – Renal impairment – Type 2 diabetes mellitus 
  
 1. Introduction 
The prevalence of type 2 diabetes mellitus (T2DM) is rapidly increasing worldwide. 
Numerous patients with T2DM have some degree of renal impairment (RI), which may be 
assessed by a reduction in glomerular filtration rate  (GFR) and classified in various stages 
according to severity (from stage 1 to stage 5)1, 2. The presence of RI may impact on the 
management of T2DM3, 4.  The prevalence of chronic kidney disease (CKD) associated with 
diabetes in the United States increased from 1988 to 2008 in proportion to the prevalence of 
diabetes and among persons with diabetes, the prevalence of CKD was stable despite the 
implementation of specific therapies5. The causes of CKD in T2DM patients are numerous, 
most generally combining the effects of diabetic nephropathy resulting from chronic 
hyperglycemia (which may remain unknown for a long time because of the lack of 
symptoms), nephroangiosclerosis secondary to arterial hypertension (a common comorbidity 
in patients with T2DM), urinary infections (generally asymptomatic), coadministered 
potentially nephrotoxic agents (among which widely used non steroidal antiinflammatory 
drugs) or simply advance in age3.    
In the US National Health and Nutrition Examination Survey (NHANES), 39.7 % of 
patients with T2DM had CKD of various degrees6.  The proportion of patients treated by at 
least one oral antidiabetic agent (OAD) significantly progresses from 36.3% in patients with 
stage 1 CKD to 62.9% in patients with stages 4-5 CKD. These observations support the 
availability of efficacious and safe glucose-lowering agents to be prescribed in T2DM patients 
with CKD. In the Kidney Early Evaluation Program (KEEP) involving 77,077 participants, 
26.2% had CKD and 29.9% had diabetes. Among those with both diabetes and CKD, only 
9.4% were aware of the existence of RI7. Interestingly, patients with a documented RI 
diagnosis have lower odds of progression to end-stage renal disease (ESRD). The presence of 
CKD may influence the adequate use of glucose-lowering agents in T2DM8-10. Not 
surprisingly, commonly prescribed OADs such as metformin and sitagliptin are frequently 
administered at inappropriate doses in patients with RI11. These observations reinforce the 
need for a better sensitization of both physicians and diabetic patients regarding the problem 
of CKD. The general objectives are that T2DM patients should be regularly checked as far as 
their renal function and that glucose-lowering agents are used in an efficacious and safe 
manner in presence of CKD12-14.   Finally, besides specific hyperglycemia management, other 
risk factors (hypertension, dyslipidemias, …) should also be treated in order to improve 
cardiovascular and renal outcomes2, 3, 12, 15. 
Evidence that intensive glucose-lowering treatment has an effect on loss of glomerular 
filtration rate (GFR) is sparse. The 2012 update of the KDOQI (Kidney Disease Outcomes 
Quality Initiative) clinical practice guidelines for diabetes and CKD recommends a target 
hemoglobin A1c (HbA1c) of  ≈ 7.0% to prevent or delay progression of the microvascular 
complications of diabetes, including CKD (level of evidence 1A);  recommends not treating to 
an HbA1c target of <7.0% in patients at risk of hypoglycemia (level of evidence 1B); and 
suggests that target HbA1c be extended above 7.0% in individuals with co-morbidities or 
limited life expectancy and risk of hypoglycemia (level of evidence 2C) 3. This patient-
centered approach is in agreement with the 2012 ADA (American Diabetes Association) – 
EASD (European Association for the Study of Diabetes) position statement16. 
 
Kidney plays a major role in the clearance of drugs, in general17, and of glucose-
lowering agents used for T2DM, in particular13. Therefore, the management of glycemia in 
patients with diabetes and CKD is quite challenging10 and the questions of which 
hypoglycemic agents to use in T2DM subjects with CKD and how to use them are of major 
practical importance18. Besides the mode of action of glucose-lowering agents19, renal 
function should also be taken into account by the physician. Indeed, the presence of RI may 
deeply impact the pharmacokinetics (PK) and thereby should influence choices, dosing, and 
monitoring of hypoglycemic agents according to the reduction of GFR9. The situation is even 
more complex in the frail elderly population, where RI and polymedication are very 
common20. 
The aim of this paper is to provide an updated analysis of the use of OADs and 
injectable agents in T2DM patients with CKD8-10. After a brief description of how to assess 
kidney function in patients with T2DM, we will describe the PK characteristics as well as the 
efficacy/safety profile of each glucose-lowering compound in patients with various degrees of 
RI (Table 1, Table 2).   
To identify relevant studies, an extensive literature search of MEDLINE was 
performed from 1970 to December 2012, with the names of the following pharmacological 
classes biguanides, sulfonylureas, meglitinides (glinides), alpha-glucosidase inhibitors, 
thiazolidinediones (TZDs), dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose 
cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, 
human insulin or insulin analogs combined with any of the following terms : “chronic kidney 
disease”, “renal insufficiency”, “renal impairment” or “nephropathy”. Each generic name - 
“metformin”, glibenclamide (glyburide), glimepiride, glipizide, gliclazide, gliquidone, 
repaglinide, nateglinide, acarbose, miglitol, voglibose, pioglitazone, rosiglitazone, sitagliptin, 
vildagliptin, saxagliptin, linagliptin, alogliptin, dapagliflozin, canagliflozin, empagliflozin, 
exenatide, liraglutide, insulin, insulin lispro, insulin aspart, insulin glulisine, insulin glargine, 
insulin detemir  - was also combined with the various terms corresponding to CKD.  No 
language restrictions were imposed. Reference lists of original studies, narrative reviews and 
previous systematic reviews were also carefully examined. 
 
2. Assessment of kidney function and stratification of CKD in diabetes 
Renal function is classically assessed by the GFR, which can be estimated by the 
creatinine clearance (CLCR) using the Cockroft-Gault formula1. However, such formula may 
be biased by body weight as a confounding factor leading to overestimation of true GFR in 
overweight/obese individuals, a common situation in patients with T2DM. Currently, the 
MDRD (« Modification of Diet in Renal Disease « ) formula is preferred as the method of 
choice for estimating GFR (eGFR), although it underestimates GFR in patients with GFR > 
60 mL/min/1.73 m² body surface area and is not validated for all populations. The 
corresponding values to the various stages of RI are summarized in Table 3. More appropriate 
new formulae have been recently proposed by nephrologists, although they are not used yet in 
clinical practice by diabetologists21. However, the coexistence of two formulae, such as 
Cockroft-Gault and MDRD, may lead to some discrepancies in dosing adjustment as recently 
illustrated with the use of sitagliptin in clinical practice22.  
 
3. Biguanides (metformin) 
Among biguanide compounds, only metformin remains on the market. The two other 
agents, phenformin and buformin, were withdrawn because of a too high risk of lactic 
acidosis, especially when the compound accumulates in case of RI23. Although this 
complication may also occur with metformin, it is a rare event when the contraindications are 
respected but, interestingly enough, also in patients who may be considered at higher risk (see 
below)24.  Metformin is currently accepted as the first choice OAD in the management of 
T2DM16. Paradoxically, there are numerous contraindications to the use of metformin because 
of a theoretical risk of lactic acidosis24. However, such a risk has been probably overestimated 
in many circumstances. Therefore, contraindications to the use of metformin may deprive 
numerous T2DM patients from a drug that may provide more benefits than risks25, 26. This is 
especially the case of patients with mild to moderate CKD who deserve much attention 
because they represent an increasing proportion of the T2DM population, notably in the 
elderly20.   
PK characteristics of metformin are well known since a long time ago27, even if new 
interesting mechanistic data have been published more recently28. Metformin is absorbed 
predominately from the small intestine and is excreted unchanged in urine. The elimination 
half-life (t1/2) of metformin during multiple dosages in patients with good renal function is 
approximately 5 hours. The population mean renal clearance (CLR) and apparent total 
clearance after oral administration (CL/F) of metformin were estimated to be (mean±SD) 
510±130 mL/min and 1140±330 mL/min, respectively, in healthy subjects and diabetic 
patients with good renal function. Over a range of renal function, the population mean values 
of CLR and CL/F of metformin are 4.3±1.5 and 10.7±3.5 times as great, respectively, as the 
CLCR. As the CLR and CL/F decrease approximately in proportion to CLCR, the dosage of 
metformin should be reduced in patients with CKD in proportion to the reduced CLCR28. 
However, rather few PK data are available in T2DM patients with various degrees of RI. 
More recent data revealed that the renal excretion of metformin (as its oral absorption and 
hepatic uptake) is mediated largely by organic cation transporters (OCTs)28. CLR of 
metformin in healthy Caucasian men varied 3.8-fold and was significantly dependent not only 
on CLCR and age but also on OCT1 polymorphisms29. Finally, promoter variants of multidrug 
and toxin extrusion protein (MATE)1 and MATE2 were recently shown to be also important 
determinants of metformin disposition, by influencing its renal and secretory clearances, and 
glucose-lowering response in healthy volunteers and diabetic patients30. 
 
3.1 PK of metformin after single dose in patients with RI 
PK parameters of metformin were determined in volunteers with normal renal function 
and in patients with different degrees of RI. The t1/2 for the elimination of metformin from 
plasma after intravenous injection was much longer (4.94±1.11 h) in patients with RI than in 
normal subjects (1.52±0.3 h). A significant correlation was observed between t1/2 and CLCR. 
After oral administration of metformin tablets, drug recovery in urines was only 37.6%, 
possibly as a consequence of binding to the intestinal wall. Metformin is rapidly eliminated 
through active secretion by the kidney, with a mean CLR of 440 ml/min (almost 3-4 times the 
value of CLCR)31. Another study  in healthy subjects and T2DM patients with various degrees 
of RI gave information about metformin clearance over a range of CLCR from 47 to 179 
mL/min. Plasma CLR of metformin was found to be highly correlated with CLCR (r = 0.85, 
P<0.001). However, a weaker relationship between total oral clearance of the drug and CLCR 
suggested that the latter may not always be a reliable indicator of potential metformin 
accumulation. CLR values for metformin well in excess of CLCR confirmed tubular secretion 
of this highly ionized compound as a major mechanism of urinary excretion32. 
In a detailed study evaluating the effects of RI and age on the PK of metformin, 
healthy adults (young, middle-age, elderly) and  adults with various degrees of CKD (mild to 
severe) were given a single, 850 mg metformin HCl tablet33. In the control group (CLCR : 
112±8 mL/min), average metformin CLR was 636±84 mL/min, whereas in mild CKD (CLCR : 
61–90 mL/min) metformin CLR was reduced at 384±122 mL/min. The mean CLR of 
metformin was lower in subjects with moderate (CLCR : 31–60 mL/min) and severe (CLCR : 
10–30 mL/min) CKD, measuring 108±57 and 130±90 mL/min, respectively. Maximum 
concentration (Cmax) and the area under the concentration time curve (AUC) were increased in 
individuals with moderate to severe CKD compared with those with mild CKD or normal 
renal function. In the moderate and severe CKD groups, all clearance values were 74-78% 
lower than in the healthy young/middle-age group, and all other evaluable PK parameters 
(with the exception of tmax) differed significantly in this group. In the mild CKD group, 
however, clearance values of metformin, which were 23-33% lower than in the young/middle-
age group, were the only parameters that differed significantly. Based on a regression analysis 
of the combined data, both CLCR and age were predictors of metformin clearance33. 
In healthy elderly subjects (mean age : 71 years; range : 65-81 years), total plasma 
clearance of metformin was decreased, the half-life was prolonged, and Cmax was increased, 
compared to healthy young subjects. From these data, it appears that the change in metformin 
PK with aging is primarily accounted for by a change in renal function. Metformin CLR 
averaged 412±98 mL/min in elderly subjects compared to 522±139 mL/min in younger 
subject (reduction by 21%)33. 
3.2 PK of metformin after multiple doses and chronic administration 
T2DM patients aged between 70-88 years received metformin at a dosage of either 
850 mg or 1,700 mg/day dependent on CLCR values of 30-60 mL/min and greater than 60 
mL/min, respectively. After 2 months, metformin concentrations remained in the therapeutic 
range and lactate levels within the reference limits in all participants, with no statistically 
differences between those with and without RI34.  
Trough serum levels of metformin were measured in 137 T2DM patients with varying 
renal function and followed repeatedly during 2 months in 20 patients with eGFR <60 
mL/min/1.73 m². Patients with eGFR >60, 30-60, and <30 mL/min/1.73 m² had median 
trough metformin concentrations of 4.5, 7.71 and 8.88 µmol/L, respectively. Notably, there 
were wide variations in these levels within each group, with few patients having serum levels 
> 20 µmol/L (> ~2.6 µg/mL). The median intra-individual overall coefficient of variation was 
around 30%35. In patients with severe RI (CLCR 15-40 mL/min), who were prescribed a range 
of metformin doses (250-2000 mg daily), few had high lactate concentrations (>2.7 mmol/L) 
and few had high metformin concentrations (3-5 mg/L), without correlation 
between metformin and lactate concentrations36. Whether the measurement of metformin 
levels actually can aid in the prediction of lactic acidosis risk remains unclear and thereby is 
not recommended in clinical practice37. 
 
3.3 Metformin and hemodialysis 
Metformin is not bound to plasma proteins, and thus should be easily dialyzable27. A 
study determined the characteristics of metformin elimination by dialysis. Metformin may be 
removed even after reaching an equilibrium between blood and dialysate levels in a 
recirculating system, suggesting a storage of metformin in a deep compartment with a 
gradient of concentration between this compartment and the blood. Metformin is highly 
dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Thus, 
hemodialysis can efficiently remove metformin, especially from patients in whom overdose is 
suspected, and corrects metabolic acidosis in patients with metformin-induced lactic 
acidosis38. Accurate recognition of metformin-associated lactic acidosis and prompt initiation 
of hemodialysis are paramount steps towards rapid recovery39. 
3.4 Controversy about the risk of metformin in patients with CKD 
Classically, CKD (CLCR < 60 mL/min) represents a contraindication to the use of 
metformin in patients with T2DM40. In case of RI, metformin may, indeed, accumulate, block 
gluconeogenesis and cause lactic acidosis, a harmful complication that may be fatal41, 42. 
However, recent data suggested that metformin may be administered with caution in patients 
with CLCR 45-60 mL/min or even lower (30-45 mL/min), provided that the daily dose is 
reduced by half and kidney function is regularly monitored37. In patients without comorbid 
conditions that would predispose them to lactic acidosis, elevated serum creatinine levels (or 
reduced GFR) should be considered a risk factor for the development of lactic acidosis but not 
an absolute contraindication43. In daily clinical practice, development of contraindications, 
including RI, rarely results in discontinuation of metformin therapy; nevertheless, lactic 
acidosis remains a rare event44, 45. In some studies, the prevalence of T2DM receiving 
metformin despite having a contraindication (including a GFR < 60 mL/min) was over 80%. 
Nevertheless, metformin use in such conditions did not appear to increase the risks of lactic 
acidosis, hospitalization and death46. At least three scenarios can be proposed to explain the 
use of metformin in patients with RI: 1) creatinine levels are not appropriately or consistently 
assessed, 2) levels are normal at the time of the initial prescription of metformin and 
subsequent elevations go unrecognized, or 3) physicians judge that benefits of therapy 
outweigh potential risks47. In patients having T2DM with established atherothrombosis 
participating in the Reduction of Atherothrombosis for Continued Health (REACH) Registry, 
the 2-year mortality rate associated with metformin vs. other glucose-lowering agents was 
significantly lower in patients with an eGFR of 30 to 60 mL/min/1.73 m² (adjusted hazard 
ratio 0.64; 95% CI, 0.48-0.86; P=0.003)48. There are more and more data suggesting that 
meformin can be used in stable mild to moderate CKD and that not prescribing metformin in 
these patients may cause more harm compared to the benefits of avoiding potentially rare 
complications25, 49, 50.  These observations led to a recent position statement from the ADA-
EASD in which metformin may be used down to a GFR of 30 mL/min, with dose reduction 
advised at 45 mL/min (Table 4). This would lead to safely prescribing OADs in patients with 
an eGFR < 60 mL/min/1.73 m², and more importantly in medical practice, according to the 
law51. However, the risk of lactic acidosis should not be neglected 42, 50, 52 and the drug should 
be immediately stopped in presence of unstable RI, any acute event (high fever for instance), 
gastrointestinal disorders (diarrhea, vomiting), dehydration, ...42, 52. 
4. Sulfonylureas  
Sulfonylureas remain largely used in the management of T2DM and are positioned as 
second-line  treatment after failure of metformin monotherapy16. They are associated with a 
higher risk of severe hypoglycemia, compared with metformin and more recent glucose-
lowering therapies53, especially in the elderly population and in patients with CKD20, 54. In a 
German study investigating the incidence of severe hypoglycemia and clinical characteristics 
to demonstrate typical risk constellations, T2DM patients were characterized by old age, low 
CLCR (46±24 mL/min) with RI in 73% and extensive co-medication55. The excessive 
mortality associated with hypoglycemia makes this complication a significant threat to patient 
safety in CKD56.  
Surprisingly, a recent retrospective analysis of the national Veterans Administration 
database showed that, compared to patients using metformin, sulfonylurea users had an 
increased risk for renal outcomes (persistent decline in eGFR from baseline of 25% or more 
or diagnosis of ESRD and/or death), with an adjusted hazard ratio of 1.2057. The reasons for 
these intriguing observations, which should be confirmed in further analyses, remain 
unknown. 
Most sulfonylureas are excreted by the kidney, either the parent compound or 
metabolites (some of them being pharmacologically active)41, 58. Clinical PK of sulfonylureas 
has been extensively reviewed59. However, rather few PK studies have been performed with 
sulfonylureas in patients with RI and most of them are rather old and of poor quality in terms 
of number of subjects and PK parameters description (Table 1). Sulfonylureas of first 
generation, like tolbutamide60 or chlorpropamide61, were shown to be excreted by the kidney, 
leading to a higher risk of severe hypoglycemia in patients with CKD. Currently, they have 
been replaced by second-generation sulfonylureas. 
   
4.1 Glibenclamide (glyburide) 
Contrasted observations regarding glibenclamide (glyburide) have been reported with 
no increase in concentrations of the parent drug in patients with various degrees of CKD, but 
a higher incidence of severe hypoglycemia reported in T2DM patients with RI. This may be 
explained by the presence of two active metabolites (M1 and M2), which are also cleared by 
the kidneys62. 
 
4.1.1 Glibenclamide PK in patients with RI  
The PK of 14C-labeled glyburide was studied in men with varying degrees of RI, who  
received a single, 5 mg oral dose of glyburide as a solution (10 microCi/ml/mg) after a high-
carbohydrate breakfast. Patients with normal to moderate RI (CLCR of 29 to 131 ml/min/1.73 
m²) had glyburide plasma t1/2 values of 2.0 to 5.0 h, with no relationship between CLCR and 
glyburide clearance. One subject with severe RI (CLCR = 5 ml/min/1.73 m²) had decreased 
glyburide clearance that resulted in a t1/2 of 11 h. The elimination of metabolites was more 
dependent on renal status but, in this study, was only significantly affected in the patient with 
severe RI63. 
The PK of glibenclamide and its active metabolites, 4-trans-hydroxyglibenclamide 
(M1) and 3-cis-hydroxy-glibenclamide (M2) was compared after a single oral 7 mg dose in 
two groups of diabetic patients with RI (iohexol clearance range : 7-42 mL/min/1.73 m²) or 
normal renal function (iohexol clearance range : 75-140 mL/min/1.73 m²)64. Peak serum 
values of M1 (24-85 vs 16-57 ng/mL) and M2 (7-22 vs <5-18 ng/mL) were higher in the 
group with RI. AUC and Cmax of glibenclamide were lower and the clearance to 
bioavailability ratio (CL/F) was higher in the RI group. In contrast, AUC and Cmax of M1 
were higher and CL/F lower in the RI group. Much lower amounts of M1 and M2 were 
excreted in the urine in the RI group (7.2% vs. 26.4% in 24 h). The fraction of the 
glibenclamide dose excreted as metabolites correlated significantly with renal function 
measured by iohexol clearance. The differences in AUC, Cmax and CL/F of glibenclamide 
may be explained by a higher free fraction in the RI group which would increase 
glibenclamide metabolic clearance. The inverse findings regarding M1 may be explained by 
the fact that the metabolites are primarily eliminated by the kidneys. As only small amounts 
of M1 and M2 were excreted in the urine, this may indicate one or several complementary 
non-renal elimination routes64. 
Finally, PK of glyburide was compared in subjects with T2DM and ESRD requiring 
hemodialysis and in T2DM patients with normal renal function. The mean serum glyburide 
blood levels and PK parameters did not differ after initial or chronic glyburide (3 mg once 
daily) administration in patients with ESRD treated with hemodialysis compared with 
controls. Glyburide t1/2 averaged 3.3 h in control subjects and 5.0 h in hemodialysis subjects65. 
 
4.1.2 Hypoglycemia in glibenclamide-treated patients with 
RI  
 
In a cohort of 33,243 sulfonylurea users, the rate of diagnosis of hypoglycemia made 
by physicians was higher for glibenclamide than for other sulfonylureas (glipizide, gliclazide, 
tolbutamide). Furthermore, RI was shown to be associated with an increased risk of 
hypoglycemia (odds ratio, OR : 4.32 ; 95% CI 2.40-7.77)66. A Canadian case-control study 
described the potentially devastating effect of sulfonylurea-based (mostly 
glibenclamide/glyburide) oral hypoglycemic therapy in patients with ESRD with the 
occurrence of severe and prolonged hypoglycemia. Patients at greatest risk appear to be those 
with reduced intake, previous hypoglycemic episodes, and longer duration of diabetes so that 
alternative drugs should be considered in these patient groups67. However, opposite 
conclusion was reported in another nested case-control study using administrative records and 
laboratory data from Ontario, Canada, which included outpatients 66 years of age and older 
with T2DM. Compared to metformin, glyburide was associated with a greater risk of 
hypoglycemia in patients with both normal [adjusted odds ratio – OR - : 9.0; 95% CI 4.9-
16.4) and impaired renal function (OR:  6.0; 95% CI 3.8-9.5). The conclusion of this 
population-based study was that RI does not augment the risk of hypoglycemia associated 
with glyburide use in T2DM patients68. Nevertheless, a one-time intervention in a risk 
reduction project decreased glyburide use over a 3-month period in elderly outpatients with RI 
without compromising glucose control and with a trend for a reduction in the incidence of 
hypoglycemia69. 
   
4.2 Glimepiride 
The PK of glimepiride was investigated in a single (3 mg)- and a multiple-dose (1-8 
mg daily over 3 months) open study in patients with T2DM and RI70. Patients were divided 
into three groups with CLCR above 50 mL/min, 20-50 mL/min and 10-20 mL/min. Mean 
relative total clearance and mean volume of distribution of  single dose of glimepiride (41.6 
mL/min and 8.47 L, respectively, in patients with CLCR above 50 mL/min) increased in 
proportion to the degree of RI (up to 91.1 mL/min and 14.98 L, respectively, when CLCR was 
below 20 mL/min), whereas the terminal t1/2 and mean time remained unchanged.  Similar 
results were obtained after multiple doses of glimepiride. Lower relative total clearance and 
CLR of glimepiride metabolites correlated significantly with lower CLCR values. Glimepiride 
was well-tolerated without drug-related adverse events. The increased plasma elimination of 
glimepiride with decreasing kidney function can be explained on the basis of altered protein 
binding with an increase in unbound drug58, 70. 
Glimepiride was associated with fewer episodes of severe hypoglycemia than 
glibenclamide in routine clinical use53. However, severe hypoglycemia did occur with 
glimepiride, especially in elderly T2DM patients with RI71. Uncritical prescription of 
sulfonylureas (including a high proportion of glimepiride in a German study) neglecting 
crucial contraindications - particularly RI - contributed substantially to the risk of 
sulfonylurea-induced hypoglycemia in these mainly geriatric patients55. 
 
4.3 Glipizide 
In healthy volunteers, the t1/2 of glipizide elimination averaged 3.3 h both after 
intravenous and oral administration. The total plasma clearance of glipizide was 42.2±5.4 
mL/min. Glipizide CLR was dependent on urinary pH, but on the average it contributed to the 
total clearance of the parent drug only by 5%72. In subjects receiving 5 mg 14C-glipizide, 85% 
of the total radioactivity in plasma corresponded to unchanged glipizide. In urine, 98% of the 
radioactivity corresponded to more polar and more readily excreted metabolites. The 
administration of 14C-glipizide to patients with RI showed that the rate of disappearance of the 
unchanged glipizide was approximately the same as in normal subjects, but that apparent t1/2 
of the hydroxylated metabolites was increased to 20 h and more. Because these metabolites 
are metabolically inactive, such accumulation of metabolites could not lead to a higher risk of 
hypoglycemia in T2DM patients with RI73. 
Glipizide (2.5 mg once daily, adjusted based on glycemic control to a 10-mg twice a 
day maximum dose) was evaluated in patients with T2DM and moderate-to-severe CKD and 
inadequate glycemic control. A higher incidence of symptomatic hypoglycemic episodes was 
observed with glipizide versus sitagliptin (17.0% versus 6.2%, respectively; P=0.001), for a 
comparable glucose-lowering efficacy, an observation similar to that previously reported in 
patients without RI74. Similar results were obtained in a recent study that compared the 
efficacy and safety of sitagliptin and glipizide monotherapy in patients with T2DM and ESRD 
on dialysis therapy75. Thus, glipizide does not increase hypoglycemia in patients with CKD 




Gliclazide is metabolized by the liver to inactive metabolites, which are eliminated 
mainly in the urine (80%). The PK of gliclazide was studied in 6 diabetic (mean CLCR=44 
mL/min) and 11 non-diabetic (mean CLCR=13 mL/min) patients with various degrees of RI, 
and compared to that of 9 healthy volunteers (mean CLCR=118 mL/min). Gliclazide was 
absorbed similarly in all three groups. Once maximum plasma levels of gliclazide had been 
reached, they tended to decline more slowly in the RI groups (mean elimination half-life in 
diabetic group: 14.8 hours and non-diabetic group: 22.4 hours) as compared to the healthy 
volunteer group (12.7 hours). However, the inter-subject variability was large and the 
differences were not statistically significant. There were no significant differences for the 
other parameters measured and no significant correlation was found between any of the 
measured PK parameters and CLCR (data only reported as abstract form)76. 
Although no extensive data are available in patients with severe RI, studies have 
shown neither PK modifications of the drug nor a higher risk of hypoglycemia in patients with 
a GFR > 40 ml/min41. In Switzerland, gliclazide is the only sulfonylurea that can be used in 
subjects with a GFR of 40-60 ml/min, but it has to be stopped once GFR falls below 40 
ml/min78. 
Since many years, gliclazide is available as a modified release formulation73. The 
long-term efficacy and safety of gliclazide modified release in T2DM patients with mild to 
moderate RI were confirmed by the results of phase III studies. Among the 507 patients who 
completed 2 study years, 20% of them had mild to moderate RI defined on CLCR between 20 
and 80 mL/min. In these patients, the mean change in HbA1c from baseline to 2 years was 
similar to that of the patients with normal renal function, with no excess of hypoglycemic 
episodes79. 
In the European GUIDE study, which randomized 845 T2DM patients (almost 42% 
with a CLCR < 80 mL/min) to either gliclazide modified release 30-120 mg daily or 
glimepiride 1-6 mg daily, gliclazide was as effective as glimepiride, but with a significantly 
lower risk of hypoglycemia80. One proposed explanation was that the two drugs show 
different PK profiles with the occurrence of an active metabolite eliminated by the kidney for 
glimepiride and no circulating active metabolite for gliclazide, consistent with the higher 
incidence of hypoglycemia in patients with RI80. 
In  the  large prospective ADVANCE (“Action in Diabetes and Vascular Disease: 
Preterax and Diamicron Modified Release Controlled Evaluation”) trial, a strategy of 
intensive glucose control, involving gliclazide (modified release) and other drugs as required, 
that lowered the glycated hemoglobin (HbA1c) value to 6.5% yielded  a 21% significant 
reduction in the incidence of nephropathy (4.1% vs. 5.2%; hazard ratio, 0.79; 95% CI 0.66-
0.93; P=0.006). The component of new or worsening nephropathy most clearly reduced 
through intensive glucose control was the development of macroalbuminuria, with only a 
trend toward a reduction in the need for renal-replacement therapy or death from renal causes 
but no effect on the doubling of serum creatinine level. In this population, which comprised a 




Gliquidone  is rapidly and almost completely absorbed after oral administration, and 
has a short elimination half-life (around 1.5 h). It is metabolized in the liver so that 
accumulation does not take place in patients with RI41, 82. However, there are no large scale 
studies published with this sulfonylurea, which is only commercialized in few countries.  
 5. Meglitinides (glinides) 
Compared to sulfonylureas, glinides are characterized by shorter half-lifes as well as 
by the absence of significant renal excretion83, 84. Thus, in principle, they may be used in 
patients with CKD, without dose adjustment85. This conclusion may be drawn from PK 
studies in patients with RI, with repaglinide86 and nateglinide (although some caution is 
required for nateglinide because of the presence of an active metabolite that is cleared by the 
kidney).87 However, there are no large scale studies having assessed both the efficacy and the 
safety of glinides in T2DM patients with CKD83. Furthermore, these compounds are exposed, 
as sulfonylureas, to drug-drug interactions88. 
5.1 Repaglinide 
PK comparison with single and multiple doses of repaglinide (2 mg repaglinide for 7 
days) was performed in subjects with normal renal function and subjects with various degrees 
of RI (mild to moderate; severe; hemodialysis). PK parameters did not show significant 
changes after single or multiple doses of repaglinide, although the elimination rate constant in 
the group with severe RI decreased after 1 week of treatment. Subjects with severe RI had 
significantly higher exposure (AUC values) after single and multiple doses of repaglinide than 
subjects with normal renal function (Table 1). No significant differences in values for serum 
Cmax or Tmax were detected between subjects with RI and those with normal renal function. 
Hemodialysis did not significantly affect repaglinide clearance. Repaglinide was safe and well 
tolerated in subjects with varying degrees of RI. Although adjustment of starting doses of 
repaglinide is not necessary for RI or renal failure, severe impairment may require more care 
when upward adjustments of dosage are made89. 
In clinical trials of up to 52 weeks' duration and in the clinical practice setting, 
recommended dosages of repaglinide (0.5-4 mg three times daily) provided effective 
glycemic control and were generally well tolerated in patients with T2DM, including those 
with RI83. Thus, repaglinide is an appropriate treatment choice, even for individuals with 
more severe degrees of RI86. 
5.2. Nateglinide 
Diabetic patients with RI or ESRD undergoing hemodialysis received a single 120 mg 
dose of nateglinide immediately before breakfast. Plasma nateglinide concentrations increased 
rapidly and similarly in patients undergoing dialysis and matched healthy subjects and was 
comparable in patients with RI and controls. There were no statistically significant differences 
for Cmax or AUC between the groups (Table 1). Nateglinide was eliminated rapidly in all 
groups (t1/2 = 1.9-2.8 h). There was no correlation between the level of renal function and 
systemic exposure. There was a low extent of renal excretion of nateglinide in healthy 
subjects (11%) and diabetic patients with RI (3%). Nateglinide was well tolerated. These data 
suggested that nateglinide is suitable for use in diabetic patients with CKD or with ESRD 
undergoing dialysis. No dose adjustment appears necessary in renally impaired patients87. 
In another study, single 90 mg dose of nateglinide was safe and effective in patients 
with renal failure90. However, repeated administrations could cause prolonged hypoglycemia 
due to accumulation of M1, a metabolite that is known to have a modest hypoglycemic 
activity91. Hemodialysis may help to eliminate excessive accumulation of M190. 
5.3 Mitiglinide 
Although mitiglinide was effective as a treatment for diabetic patients on hemodialysis  
therapy, it should be initiated at a lower dose in this population, compared with the general 
population of diabetic patients, in order to avoid hypoglycemia92. 
 
6. Alpha-glucosidase inhibitors 
 Alpha-glucosidase inhibitors are not recommended as part of the management of 
T2DM in the recent ADA-EASD position statement16, most probably because of their lower 
glucose-lowering efficacy and of their rather poor gastrointestinal tolerance in Caucasian 
people. Nevertheless, they are a popular therapy in Asian countries. Various compounds 
belong to this pharmacological class, but the available data regarding their use in patients with 
CKD are rather scarce13. Because of their PK characteristics, no dose adjustment is required 
in case of RI, although their use in patients with moderate to severe CKD is not recommended 
in absence of  available data41.  
 
6.1  Acarbose 
Acarbose acts locally within the gastrointestinal tract and is characterized by a low 
systemic bioavailability93. Although <2% of an oral dose of acarbose was absorbed as active 
drug, patients with severe RI (CLCR <25 mL/min) attained increases about 5-fold higher for 
peak plasma concentration of acarbose and 6-fold higher for AUC values than subjects with 
normal renal function13. Because long-term clinical trials in diabetic patients with significant 




Miglitol is systemically absorbed but is not metabolized, and is rapidly eliminated by 
renal excretion as unchanged drug94. Patients with CLCR <25 mL/min taking miglitol 25 mg 3 
times daily exhibited a greater than 2-fold increase in miglitol plasma levels when compared 
to subjects with CLCR  >60 mL/min13. Dose adjustment to correct for the increased plasma 
concentrations is not feasible because miglitol acts locally in the gut. Treatment of patients 
with CLCR <25 mL/min with miglitol is not recommended because the safety of miglitol in 
these patients has not yet been elucidated13. 
 
6.3 Voglibose 
Voglibose is an alpha-glucosidase inhibitor only commercialized in Japan. It has no 
renal excretion13. Two studies showed that it can be safely used in diabetic patients on 
hemodialysis, in combination with pioglitazone or mitiglinide95, 96.  
 
 
7. Thiazolidinediones  
The experimental studies that evaluated the potential beneficial effects of peroxisome 
proliferator-activated receptor-gamma (PPARγ) agonists (TZDs : pioglitazone, rosiglitazone) 
on renal function have been reviewed. In that paper, the efficacy, tolerability and safety 
results of TZD use in patients with different degrees of RI, in dialysis patients, and in diabetic 
patients after kidney transplantation were revised97. Data from several animal and human 
studies support the notion that TZDs reduce urine albumin excretion and may prevent 
development of renal injury98.  From a PK point of view, TZDs are metabolized in the liver 
and not excreted by the kidney. Therefore, no dose adjustments are required in patients with 
CKD.  However, the safety of TZDs has been questioned and some safety concerns may be 
even more relevant in a diabetic population with CKD99. The risk of fluid retention and 
congestive heart failure, a well known adverse event associated with TZD therapy100, may be 
a concern, especially in the fragile population with CKD. Preclinical and pilot clinical data 
attest to the fact that at least part of the fluid retention derives from a direct effect of TZDs on 
sodium reabsorption via the renal medullary collecting duct. This mechanism is sensitive to 
diuretic agents that have this nephron segment as their site of action (spironolactone, 
amiloride and hydrochlorothiazide) but the efficacy of those diuretics is limited and/or their 
safety is questionable in patients with CKD100. Furthermore, TZDs may increase the incidence 
of bone fractures101, a complication already more frequently observed in patients with CKD 
independently of TZD therapy because of  insufficient vitamin D activation and renal 
osteodystrophy. Finally, cardiovascular safety of TZDs, especially rosiglitazone, has been 
questioned99 and it is well known that T2DM patients with CKD are at higher risk of 
cardiovascular complications. Contradictory results have been reported regarding the 
mortality in diabetic patients with ESRD treated by dialysis and receiving TZD therapy with 
either increased mortality102 or better survival103. Thus, despite favorable PK properties, TZDs 
do not appear as the drug of choice in T2DM patients with CKD. Nevertheless, a small study 
showed that TZD therapy was safe and effective for ambulatory patients receiving 
hemodialysis, even if some cases of heart failure have been reported104.  
 
7.1 Pioglitazone 
Because pioglitazone and its active metabolites are excreted mainly via the liver, these 
PK properties are ideally suited for patients with CKD105. Healthy subjects with normal renal 
function (CLCR > 80 mL/min), patients with moderate RI (CLCR 30-60 mL/min) and patients 
with severe RI (CLCR < 30 mL/min) received single and multiple oral doses of pioglitazone 
45 mg. The serum PK profiles of pioglitazone and its metabolites M-III and M-IV were 
assessed for the first and last dose administered (day 1 and day 12, respectively). PK data 
were similar in subjects with normal and with moderate RI and revealed no significant 
accumulation of pioglitazone or its metabolites in patients with RI. Mean AUC values were 
decreased (rather than increased) in patients with severe RI compared with healthy subjects 
with normal renal function for pioglitazone and its M-III and M-IV metabolites (Table 1) This 
may be explained by reduced protein binding, which is common in patients with RI, resulting 
in increased free pioglitazone concentrations and increased total clearance of the drug 
(assuming that the intrinsic capacity of the liver remains unchanged). In this study, 
pioglitazone was well tolerated in patients with varying degrees of RI so that adjustment of 
starting and maintenance doses in these patients is probably unwarranted106.  PK profile of 
pioglitazone was also shown to be similar in patients with ESRD undergoing hemodialysis 
and in patients with normal renal function107. In T2DM patients on hemodialysis, pioglitazone 
treatment resulted in better glycemic control, improved lipid levels, an increase in insulin 
sensitivity and adiponectin levels, a decrease in inflammatory markers and a reduction in 
erythropoietin dose, thus improving the risk factors of cardiovascular disease108. Interestingly, 
a post hoc analysis from PROactive (“PROspective pioglitAzone Clinical Trial In 
macroVascular Events”) investigated the effects of pioglitazone 45 mg treatment on recurrent 
CV disease in a population of patients with T2DM and documented macrovascular disease 
according to the level of GFR. Patients who had CKD (eGFR < 60 mL/min/1.73m²) and were 
treated with pioglitazone were less likely to reach a composite endpoint of all-cause death, 
myocardial infarction and stroke (HR=0.66, 95% CI 0.45-0.98), independent of the severity of 
RI 109, 110.  
7.2 Rosiglitazone 
Rosiglitazone is mainly metabolized by CYP2C8 into inactive metabolites, and < 1% 
of the parent drug appears in the urine in unchanged form111. To investigate the effect of 
varying degrees of  CKD on the PK  of rosiglitazone after a single dose of 8 mg, subjects 
were stratified by estimated CLCR : normal (> 80 mL/min), mild RI (60-80 mL/min), 
moderate RI (30-59 mL/min), and ESRD not requiring dialysis (< 30 mL/min)112. Slight 
increases (approximately 10%-20%) in mean unbound AUC∞ values were observed for each 
RI group compared to the normal group but were not considered to be clinically relevant. 
Patients with severe RI exhibited a 38% increase in mean fraction unbound, leading to an 
increase in total clearance, which resulted in a 19% to 24% lower mean total AUC∞ and Cmax 
values relative to the normal group. The rates of adverse events were similar for all groups. 
As RI does not markedly alter the PK of total or unbound rosiglitazone following a single 
dose of rosiglitazone, the starting dose does not need to be adjusted in patients with CKD. 
Subsequent dose adjustments should be based on individual patient response112. 
The PK and tolerability of a single 8 mg oral dose of rosiglitazone were compared in 
ESRD patients undergoing hemodialysis and 10 healthy volunteers. Hemodialysis did not 
influence rosiglitazone PK, and dialytic clearance was low (0.10 L/h). Mean AUC∞, Cmax and 
t1/2 for rosiglitazone were similar in hemodialysis patients and healthy individuals. Thus, 
rosiglitazone dose adjustments are not warranted in patients with T2DM with ESRD on 
hemodialysis113. The PK of a single 8 mg oral dose of rosiglitazone was studied in patients 
with ESRD and requiring long-term chronic ambulatory peritoneal dialysis. Mean AUC∞ and 
Cmax of rosiglitazone in patients with peritoneal dialysis appear no different from those 
reported in healthy volunteers114. 
In a post-hoc analysis of data pooled from 3 randomized, double-blind, placebo-
controlled studies, the effects of rosiglitazone 4 mg when added to a sulfonylurea regimen 
were investigated in patients with T2DM and mild to moderate RI (baseline CLCR of 30 to 80 
mL/min). Rosiglitazone was effective and well tolerated in this population, with no obvious 
differences with results observed in patients with normal kidney function115. In two other 
studies, rosiglitazone was well tolerated and beneficial in patients with T2DM on peritoneal 
dialysis therapy116 or undergoing regular hemodialysis117. 
 
8. DPP-4  inhibitors  
DPP-4 inhibitors (gliptins) are a new class of OADs belonging to the incretin-based 
glucose-lowering agents. They improve glucose control without inducing hypoglycemia (in 
contrast to sulfonylureas) and are weight-neutral118. Several molecules are already available, 
which are characterized by different PK properties119, 120. DPP-4 inhibitors have been  
particularly well studied in patients with CKD121. Sitagliptin,122 vildagliptin123, 124, 
saxagliptin125 and alogliptin126 are largely excreted by the kidneys. Results from dedicated PK 
studies in subjects with various degrees of RI suggest that the daily doses of these four DPP-4 
inhibitors should be adjusted according to eGFR to reach almost similar plasma levels121. 
Several studies have demonstrated that the glucose-lowering efficacy is maintained while a 
good safety profile when reduced doses of these gliptins are used in patients with RI127-130. In 
contrast, linagliptin is mainly excreted by the biliary route rather than by the kidney (< 5 
%)131. Therefore, this DPP-4 inhibitor does not require any dose adjustment in case of RI and 
can be used in patients with various degrees of CKD (Table 5)132, 133. In all studies involving 
DPP-4 inhibitors, the following populations were tested : normal kidney function, CLCR > 80 
ml/min; mild RI, 50–80 mL/min; moderate RI, 30–50 mL/min; severe RI, <30 mL/min; 
ESRD, <30 mL/min undergoing hemodialysis. 
DPP-4 inhibitors are playing an increasing role in the management of T2DM, 
especially in combination with metformin. Several fixed-dose combinations (FDCs) are 
currently available or will be commercialized very soon118. Such FDCs may only be 
prescribed when both compounds are not contraindicated because of the presence of RI and 
appropriate adjustments of individual doses may be required134-136.       
 
8.1 Sitagliptin 
The PK of single doses of sitagliptin 50 mg was evaluated in patients with various 
degrees of RI : mild, moderate, severe, ESRD on hemodialysis, and normal  renal function122.  
Increases in sitagliptin AUC∞ were ∼1.6-fold, ∼2.3-fold, ∼3.8-fold, and ∼4.5-fold higher for 
patients with mild, moderate, severe RI and ESRD, respectively, as compared to levels 
obtained in subjects with normal renal function (Table 1). Based on these findings, sitagliptin 
dose adjustments are recommended for patients with moderate RI (50 mg daily) or severe RI 
or ESRD (25 mg daily) to provide plasma sitagliptin exposure comparable to patients with 
normal renal function (100 mg daily) (Table 5).  
Sitagliptin was generally well tolerated and provided effective glycemic control in 
patients with T2DM and moderate to severe RI, including patients with ESRD on dialysis128. 
In patients with T2DM and moderate to severe CKD, sitagliptin (50 to 25 mg/day 
respectively) and glipizide provided similar HbA1c-lowering efficacy. Sitagliptin was 
generally well-tolerated, with a lower risk of hypoglycemia and weight loss versus weight 
gain, relative to glipizide74. In patients with T2DM and ESRD on dialysis therapy, sitagliptin 
25 mg/day was almost as effective in reducing HbA1c as glipizide (non significant difference 
of 0.15% after 54 weeks), with a lower incidence of symptomatic hypoglycemia (6.3 % vs. 
10.8%) and severe (0% vs. 7.7%) hypoglycemia75. 
 
8.2 Vildagliptin 
Vildagliptin is primarily metabolized via hydrolysis and the metabolites are 
predominantly excreted by the kidneys. To a smaller extent, vildagliptin is also excreted by 
the kidneys as the unchanged drug (23% after an oral dose). Therefore, RI may have certain 
effects on the PK of vildagliptin123. The mean AUC values increased by 32–134% and the 
Cmax values increased by 8–66% in subjects with mild, moderate and severe RI, and ESRD on 
hemodialysis, compared with healthy subjects. CLR of vildagliptin in healthy volunteers 
averaged 12.4 L/h, and decreased in subjects with varying degrees of RI  with a significant 
correlation with the reduction in GFR (r²=0.75). However, the total exposure (AUC) to 
vildagliptin did not show a clear correlation with the severity of RI (assessed by GFR). 
Vildagliptin was removed by hemodialysis to a limited extent (3%).  Compared with values in 
healthy subjects, exposure (AUC) to the major and inactive hydrolysis metabolite (LAY151) 
in subjects with mild, moderate and severe RI, and in those with ESRD was increased by 1.6-, 
2.4-, 5.4- and 6.7-fold, respectively, with a good correlation between changes in exposure to 
LAY151 and GFR reduction124 (Table 1). The lack of a clear correlation between the 
increased exposure to vildagliptin and the severity of RI may indicate that the kidneys 
contribute not only to the excretion but also, and predominantly, to the hydrolysis metabolism 
of vildagliptin. From a PK perspective, the approximate 2-fold increase in exposure suggests 
that the dose of vildagliptin for patients with moderate and severe RI should be reduced to 
half of the daily dose for patients with normal renal function (50 mg once daily instead of 50 
mg twice daily) (Table 5)123. 
In a 24-week study of 515 patients with T2DM and moderate or severe RI, vildagliptin 
(50 mg once daily) added to ongoing antidiabetic therapy had a safety profile similar to 
placebo and elicited a statistically and clinically significant decrease in HbA1c129. These 
results were confirmed after a 1-year observation130. In another study, the safety profile of 
vildagliptin 50 mg as an add-on to metformin was similar in patients with mild RI and normal 
renal function137. In a pooled analysis of 38 studies where vildagliptin was given for 12-104 
weeks in patients with T2DM, the presence of mild RI did not adversely affect the safety of 
vildagliptin relative to patients with normal renal function138. Finally, vildagliptin was also 
effective and safe as a treatment for diabetic patients undergoing hemodialysis139 or in 
patients with severe RI (eGFR < 30 mL/min/1.73 m² and longstanding T2DM not adequately 
controlled with insulin therapy140. 
 
8.3 Saxagliptin 
The PK of saxagliptin and its pharmacologically active metabolite, 5-hydroxy 
saxagliptin, in nondiabetic subjects with mild (CLCR 50–80 ml/min), moderate (30–50 
ml/min), severe RI (<30 ml/min), or ESRD were compared with saxagliptin and metabolite 
PK and tolerability in healthy adult subjects.125 All subjects received a single oral dose of 
saxagliptin 10 mg. Using a model-based approach and compared with healthy subjects, the 
geometric mean AUC∞ for saxagliptin was 16%, 41% and 108% higher in subjects with mild, 
moderate or severe RI, respectively. AUC∞ values for 5-hydroxy saxagliptin were 67%, 192% 
and 347% higher in subjects with mild, moderate or severe RI, respectively (Table 1). 
Elimination t1/2 of saxagliptin and 5-hydroxy saxagliptin progressively increased while 
corresponding CLR progressively decreased according to the reduction of CLCR. 
Consequently, one-half the usual dose of saxagliptin 5 mg (i.e. 2.5 mg orally once daily) is 
recommended for patients with moderate or severe RI or ESRD on hemodialysis, but no dose 
adjustment is recommended for those with mild RI. 
A 12-week study evaluated the efficacy and safety of saxagliptin 2.5 mg versus 
placebo in patients with T2DM and RI (CLCR < 50 mL/min)141. Oral antihyperglycemic drugs 
and insulin therapy present at enrolment were continued throughout the study. Adjusted mean 
HbA1c decreases from baseline to week 12 were numerically greater with saxagliptin than 
with placebo in the subgroups of patients with moderate (≥ 30 CLCR < 50 mL/min) and severe 
(CLCR < 30 mL/min) RI, but not in ESRD patients on hemodialysis. After an extended follow 
up of 52 weeks, adjusted mean decrease in HbA1c was greater with saxagliptin than placebo 
(difference, -0.73%, p<0.001). Reductions in HbA1c were numerically greater with saxagliptin 
2.5 mg than placebo in patients with RI rated as moderate or severe, but similar to placebo for 
those with ESRD on hemodialysis. Saxagliptin was generally well tolerated, with similar 
proportions of patients reporting hypoglycemic events as in the placebo group. Thus, 
saxagliptin 2.5 mg once daily offers sustained efficacy and good tolerability for patients with 




The results of a single-dose (50 mg) PK study in patients with RI showed an increase 
in alogliptin exposure compared with healthy volunteers: approximately 1.7-, 2.1-, 3.2-, and 
3.8-fold increase in patients with mild, moderate, and severe RI, and in patients with ESRD, 
respectively (Table 1)126. Based on these findings, to achieve plasma alogliptin concentrations 
comparable to those in patients with normal renal function, alogliptin dose adjustments are 
recommended for patients with T2DM and moderate to severe RI, including those with ESRD 
requiring dialysis (Table 5). 
 
8.5 Linagliptin 
The influence of various degrees of RI on the exposure of linagliptin was assessed in 
subjects with and without T2DM142.  Linagliptin PK (5 mg once daily) was studied under 
single-dose and steady-state conditions (administration for 7-10 days) in subjects with mild, 
moderate, and severe CKD and ESRD on hemodialysis, and compared with the PK in subjects 
with normal renal function. Renal excretion of unchanged linagliptin was <7% in all groups. 
Although there was a tendency towards slightly higher (20-60%) exposure in subjects with 
CKD compared with subjects with normal renal function, the steady-state AUC and Cmax 
values showed a large overlap and were not affected by the degree of RI (Table 1). Thus, 
CKD has a minor effect on linagliptin PK, a finding that has been confirmed in post-hoc 
analyses of the trough plasma levels of linagliptin in the global Phase III program 
investigating linagliptin 5 mg once daily for 24-52 weeks in patients with T2DM and various 
degrees of RI143.  
A pooled analysis of 3 clinical trials evaluated the effect of renal function on the 
efficacy and safety of linagliptin. Data were available for 2,141 patients with T2DM who 
were grouped by renal function as normal (n=1684), mild CKD (n=418), or moderate CKD 
(n=39). Linagliptin showed consistent placebo-corrected adjusted mean HbA1c changes after 
24 weeks across all 3 groups: normal renal function (-0.63%), mild CKD (-0.69%), and 
moderate CKD (-0.69%), with no significant inter-group difference. Linagliptin was generally 
well tolerated, with an incidence rate of adverse events with linagliptin similar to placebo.132 
Finally, a recent phase 3 trial evaluated the efficacy and safety of linagliptin in patients 
with T2DM and severe CKD (GFR <30 mL/min/1.73 m2).133  Patients were treated with either 
linagliptin 5 mg once daily or placebo. Linagliptin induced significantly greater HbA1c 
reductions at week 12 compared to baseline in the full analysis set (-0.8% versus -0.2% with 
placebo) and in the subgroup of poorly controlled patients (baseline HbA1c ≥9%) (-1.5% vs. -
0.3%). Hypoglycemia occurred more frequently in linagliptin-treated patients than in placebo-
treated patients, an observation that may be explained by unchanged doses of insulin and/or 
sulfonylurea background therapy. Other adverse event rates were similar for linagliptin and 
placebo.  
 
9. SGLT2 inhibitors 
The kidney plays a major role in glucose homeostasis because of its role in 
gluconeogenesis and the glomerular filtration and reabsorption of glucose in the proximal 
convoluted tubules. The transport of glucose from the tubule into the tubular epithelial cells is 
accomplished by sodium-glucose co-transporters (SGLTs), especially SGLT2, a high-
capacity, low-affinity transporter expressed chiefly in the kidney. SGLT2 accounts for 
approximately 90% of glucose reabsorption. SGLT2 inhibitors are new glucose-lowering 
agents, which specifically target the kidney by blocking the reabsorption of filtered glucose, 
thus leading to glucosuria. This mechanism of action holds potential promise for patients with 
T2DM not only in terms of improvements in glycemic control, but also potential benefits on 
weight loss and arterial blood pressure reduction144. Dapagliflozin is the SGLT2 inhibitor with 
the most clinical data available to date145. Other SGLT2 inhibitors (canagliflozin, 
empagliflozin) are currently in late phase of development, but no specific PK studies in 
patients with RI have been published so far with these last two compounds144. In a study 
investigating potential drug-drug interactions between empagliflozin and metformin in 
healthy men, the renal clearance of empagliflozin and metformin were unaffected by co-
administration146. 
A study assessed the effect of differences in renal function on the PK/PD of 
dapagliflozin. A single 50 mg dose of dapagliflozin was administered in five groups of 
individuals: healthy nondiabetic subjects; patients with T2DM and normal kidney function; 
and patients with T2DM and mild, moderate or severe RI based on eGFR. Subsequently, 
multiple doses (20 mg once daily) were evaluated in the patients with T2DM. Plasma 
concentrations of dapagliflozin and D3OG, an inactive metabolite, were incrementally 
increased with declining kidney function. Steady-state Cmax for dapagliflozin were 4%, 6% 
and 9% higher and for D3OG were 20%, 37% and 52% higher in patients with mild, 
moderate, and severe RI, respectively, compared to normal function. AUC0-tau was likewise 
higher (Table 1). Compared to patients with normal renal function, glucose-lowering effects 
were attenuated with RI. Steady-state renal glucose clearance was reduced by 42%, 83%, and 
84% in patients with mild, moderate, or severe RI, respectively. These results indicate that the 
kidney, besides the liver, significantly contributes to dapagliflozin metabolism, resulting in 
higher systemic exposure with declining kidney function. Dapagliflozin reduced 
pharmacodynamics in diabetic subjects with moderate to severe RI are consistent with the 
observation of reduced efficacy in terms of HbA1c diminution in this patient population147.  
 
10. GLP-1 receptor agonists 
When oral therapy is not sufficient to control blood glucose, injectable agents may be 
used. Besides insulin therapy, GLP-1 receptor agonists (exenatide and liraglutide, soon 
lixisenatide) offer new opportunities for the management of T2DM16. However, because of 
PK properties of these compounds, some limitations have been pointed out in presence of RI 
(Table 5). 
Published case reports have documented the relationship between exenatide148, 149 or 
liraglutide150 use and acute kidney injury in patients with T2DM. The proposed explanation 
was the occurrence of gastrointestinal side effects with recurrent vomiting leading to 
dehydration and secondary acute RI. Physicians should be aware of this adverse event and 
patients should also be educated about the need to report unusual or prolonged gastrointestinal 
symptoms. However, a retrospective cohort study of a large medical and pharmacy claims 
database revealed an increased incidence of acute renal failure in diabetic versus non-diabetic 
patients but no association between use of exenatide and acute renal failure151. 
 
10.1 Exenatide 
PK, safety and tolerability of a single exenatide dose were evaluated in patients with 
RI. Exenatide (5 or 10 µg) was injected subcutaneously in 31 subjects (only one with T2DM) 
stratified by renal function : normal (CLCR >80 mL/min, mild RI (51-80 mL/min), moderate 
RI (31-50 mL/min) or end-stage renal disease (ESRD) requiring hemodialysis152. PK data 
were combined with four previous single-dose studies in patients with T2DM to explore the 
relationship of exenatide clearance (CL/F) and CLCR. Mean t1/2 for healthy, mild RI, moderate 
RI and ESRD groups were 1.5, 2.1, 3.2 and 6.0 h, respectively. After combining data from 
multiple studies, least squares geometric means for CL/F in subjects with normal renal 
function, mild RI, moderate RI and ESRD were 8.14, 5.19, 7.11 and 1.3 L/h, respectively. 
Thereby, exposure (AUC) to exenatide was markedly increased in patients with ESRD (Table 
1). Exenatide was generally well tolerated in the mild and moderate RI groups, but not in 
subjects with ESRD due to nausea and vomiting. Since tolerability and PK changes were 
considered clinically acceptable in patients with mild to moderate RI, it would be appropriate 
to administer exenatide to these patients without dosage adjustment. However, poor 
tolerability and significant changes in PK make the currently available therapeutic doses (5 
and 10 µg) unsuitable in severe RI or ESRD152. 
 
10.2 Liraglutide 
To investigate whether dose adjustment of the once-daily human GLP-1 analogue 
liraglutide is required in patients with varying stages of RI, 30 subjects were given a single 
dose of liraglutide, 0.75 mg subcutaneously. No clear trend for change in PK was evident 
across groups with increasing renal dysfunction. The regression analysis of log(AUC) for 
subjects with normal renal function and mild-to-severe RI showed no significant effect of 
decreasing CLCR on the PK of liraglutide. Degree of RI did not appear to be associated with 
an increased risk of adverse events. Because renal dysfunction was not found to increase 
exposure of liraglutide, T2DM patients with RI should use standard treatment regimens of 
liraglutide. There is, however, currently limited experience with liraglutide in patients beyond 
mild-stage CKD153.  
To determine the effect of mild RI on the efficacy and safety of liraglutide in patients 
with T2DM, the six LEAD (“Liraglutide Effect and Action in Diabetes”) clinical trials were 
examined in a meta-analysis focusing on data from patients with normal renal function 
(CLCR > 89 mL/min), mild RI (60-89 mL/min), and moderate or severe RI (< 60 mL/min). 
The population contained patients administered once-daily liraglutide (1.2 or 1.8 mg) or 
placebo as either monotherapy or in combination with oral antidiabetes drugs for 26 weeks. 
Mild RI did not affect the estimated treatment differences in HbA1c, body weight and systolic 
blood pressure. Liraglutide treatment was safe and well tolerated in patients with mild RI, as 
there were no significant differences in changes in rates of renal injury, minor hypoglycemia, 
or nausea vs. placebo. Nevertheless, a trend towards increased nausea was observed in 
patients with moderate or severe RI receiving liraglutide although the number of patients in 
this treatment group was too low to determine statistical significance. The conclusion was that 
mild RI had no effect on the efficacy and safety of liraglutide154. 
 
11. Insulin and insulin analogs 
11.1 Human Insulin 
The kidney plays a pivotal role in the clearance and degradation of circulating 
insulin155. Almost 50% of circulating insulin (a higher proportion for exogenous than 
endogenous insulin) is cleared by the kidneys via two distinct routes : 1) glomerular filtration 
and subsequent luminal reabsorption of insulin by proximal tubular cells by means of 
endocytosis; and 2) diffusion of insulin from peritubular capillaries and subsequent binding of 
insulin to the contraluminal membranes of tubular cells. As renal failure progresses, 
peritubular insulin uptake increases, compensating for the decline in degradation of filtered 
insulin until the GFR decreases to less than approximately 20 mL/ min. With lower levels of 
GFR insulin clearance decreases further and overall requirements for exogenous insulin often 
decline. If this is not anticipated, the risk of symptomatic hypoglycemia can increase. 
The effect of diabetic nephropathy (Kimmelstiel-Wilson syndrome) on insulin 
requirements is known for a long time156. Impairment of the CLR of insulin prolongs the t1/2 of 
circulating insulin and often results in a decrease in the insulin requirement of diabetic 
patients157.  It is generally recommended that when the GFR decreases to between 10 and 50 
mL⁄ min, the insulin dosage should be reduced by 25%, and when the GFR decreases to <10 
mL⁄min, the insulin dosage should be reduced by 50% from previous amounts8, 9. The 
reduction in insulin requirement in RI is similar in type 1 and insulin-treated T2DM patients. 
In subjects with T2DM, the residual insulin secretion has no impact on the reduction in 
insulin requirement dependent on the GFR. As an example, the insulin dose required by 
T2DM patients was reduced by 51% in patients with a CLCR of 10 mL/min compared to 
patients with a CLCR of 80 mL/min158. 
11.2. Insulin analogs 
Modifications of the insulin molecule have resulted in two long-acting insulin analogs 
(glargine and detemir) and three rapid-acting insulins (aspart, lispro, and glulisine) with 
improved PK/PD profiles. As for human insulin, the PK/PD profiles for insulin analogs may 
be influenced by many variables including renal function, although the available data are 
rather scarce159. Insulin lispro maintains its characteristic PK/PD properties in patients with 
overt diabetic nephropathy160. In hemodialysis patients with diabetes, lispro insulin is 
absorbed faster than regular insulin, as it is in individuals with normal kidney function161. 
Similarly, RI does not affect the PK of insulin aspart in a clinically significant manner162. To 
our knowledge, there are no published studies that have specifically tested the PK of the two 
long-acting insulin analogs, glargine or detemir, in patients with CKD159. Reduction of initial 
glargine/glulisine insulin weight-based dosing in hospitalized patients with T2DM and RI 
reduced the frequency of hypoglycemia by 50% without compromising the control of 
hyperglycemia163. Short-acting insulin analog can also be used in hemodialysis patients with 
T2DM164. 
12. Conclusion 
  A quite large and increasing proportion (currently around 20-25%) of T2DM patients 
have moderate to severe CKD (stages 3-5), especially in the elderly population, which 
requires the adaptation of the glucose-lowering therapy. Indeed, RI exerts a major influence 
on PK of most oral and injectable antidiabetic agents. Therefore, the daily dosage should be 
reduced in most instances or, if CKD is severe enough, the medication should not be initiated 
or be stopped for safety reasons (Figure 1). Clinical experience in various countries, however, 
demonstrates that numerous T2DM patients are not appropriately treated, as they are 
receiving too high dosages of the medications according to the reduced renal function or even 
they are treated by drugs that are contraindicated considering the severity of CKD. Despite 
these inappropriate prescriptions, the incidence of severe adverse events is rather low, even if 
it may be somewhat underestimated in clinical practice. The most well recognized side effects 
when glucose-lowering drugs are prescribed in T2DM patients with RI are lactic acidosis with 
metformin, hypoglycemia with sulfonylureas (more rarely with glinides) but also with insulin 
(or insulin analogs), and fluid retention with a higher risk of congestive heart failure with 
TZDs. The PK of DPP-4 inhibitors (except linagliptin) and GLP-1 receptor agonists is also 
modified by RI, which may require appropriate dose reductions. However, the potential risk 
associated with these compounds, even if used in patients with CKD, is less well established. 
Whatsoever, the risk of hypoglycemia that may be dangerous, and even fatal, with 
sulfonylureas in patients with CKD could be markedly reduced by using DPP-4 inhibitors 
instead of sulfonylureas in this population. The case of metformin deserves more attention. 
Indeed, metformin is the first-line OAD in all guidelines for the management of T2DM, but it 
is also officially contraindicated in patients with GFR below 60 mL/min. If this rule is strictly 
respected (which is frequently not the case in real life !), this will deprive numerous patients 
of the best glucose-lowering agent. This situation should lead to an amendment of the rules of 
prescription of metformin in patients with mild to moderate RI. Finally, the experience with 
SGLT2 inhibitors, the only glucose-lowering drugs that specifically target the kidney, is still 
limited, although this new pharmacological class has already shown a reduced 
pharmacodynamic activity in patients with CKD and thereby is not best suited for this 
population.  
The increasing prevalence of patients with T2DM and CKD, especially among elderly 
people, requires regular monitoring of renal function and appropriate selection and dosing of 
glucose-lowering agents according to GFR. A careful benefit/risk balance assessment should 
be performed in these more fragile diabetic patients. It would be of clinical interest in the 
future to develop new antidiabetic agents that may be used efficaciously and safely in the 
large population with T2DM and CKD.  
 
EXPERT OPINION SECTION 
According to the recent ADA-EASD position statement, the management of 
hyperglycemia of T2DM should be patient-centered. Generally speaking, the objectives and 
the modalities of therapy should be adapted to the characteristics of the T2DM patient. CKD 
is a common complication of T2DM, especially in the elderly population whose proportion is 
rapidly increasing, notably because of a better cardiovascular protection of patients with 
T2DM. The first step is to use appropriate methods to quantitatively assess and follow renal 
function. Current non-uniform use of different equations leads to more confusion rather than 
help with renal dosing and there is need for greater standardization of eGFR estimations. 
Secondly, in a patient-centered approach, the presence of CKD is obviously an important 
condition to be taken into account, more specifically in the selection, dosing and supervision 
of pharmacological therapies.  In T2DM patients with CKD, the treatment algorithm that may 
be proposed is the following one, although there are no official guidelines in this specific 
population.   
- The first choice drug may remain metformin provided that RI is stable, the CLCR is 
above 30 ml/min and the renal function can be regularly monitored. When CLCR is 
below 45 ml/min, the daily dose of metformin should be reduced by half and the 
medication should be stopped when CLCR falls below 30 ml/min. Noteworthy, the 
patient and his/her family should be duly informed that metformin must be stopped in 
any acute condition, especially any situation that may lead to dehydration (diarrhea, 
vomiting, …) to reduce the risk of lactic acidosis (a rare but possibly fatal 
complication). 
- In case of contraindication to metformin (CLCR between 30-45 ml/min but at risk of 
destabilisation or CLCR < 30 ml/min), the physician may chose a DPP-4 inhibitor 
rather than a sulfonylurea in order to reduce the incidence of sulfonylurea-associated 
hypoglycemia in patients known to be exposed to this severe complication. 
Linagliptin, which is not excreted by the kidneys, may be administered at the usual 
dose whereas the daily dose of other DPP-4 inhibitors should be reduced (generally by 
half) to reach comparable plasma levels. Thereby, a similar glucose-lowering activity 
can be achieved, with a good safety profile, in T2DM patients with moderate to severe 
CKD as compared to patients with normal kidney function. Alternatively, to reduce 
the cost, a glinide or a sulfonylurea with low renal excretion (and without active 
metabolite) may also be considered. A thiazolidinedione (currently pioglitazone only, 
as rosiglitazone is now withdrawn in most countries because of cardiovascular safety) 
may also be used without dosage adjustment, although the risk of fluid retention and 
congestive heart failure may be increased in more fragile patients with CKD.  In the 
Asian population, alpha-glucosidase inhibitors might also be a valuable option, 
although almost no data are available in CKD patients with this pharmacological class 
that deserves further specific studies in this population.    
- When individually-targeted glucose control cannot be achieved or maintained with 
metformin monotherapy, the addition of a DPP-4 inhibitor appears to offer some 
advantages compared to sulfonylureas (again, less hypoglycemia, no weight gain, no 
need of titration). Several gliptin plus metformin FDCs are currently available to 
facilitate the use of such combination and improve adherence to therapy. The above-
mentioned pharmacological alternatives (repaglinide, pioglitazone, acarbose) may also 
be considered, although few controlled clinical trials are available in this population 
with CKD and thus the clinical evidence is rather scarce.  
- When the gliptin-metformin combination fails, the shift to insulin therapy is probably 
the best option, owing to the current limited experience with triple oral therapies or 
injectable GLP-1 receptor agonists in patients with CKD. It is worth noting that 
insulin daily doses are generally lower in patients with CKD than in patients without 
CKD, because the kidneys clear about 50% of circulating insulin and diabetic patients 
with RI are more exposed to hypoglycemia. The PK of various insulin preparations 
(including insulin analogs) has not been well studied in patients with varying degrees 
of RI, and there are no absolute guidelines defining appropriate dosing adjustments of 
insulin that should be made based on the level of GFR. 
- Finally, SGLT2 inhibitors are the only antidiabetic agents that specifically target the 
kidney to improve glucose control. However, their clinical efficacy vanishes as renal 
function diminishes so that these novel glucose-lowering medications should not be 
used in patients with CKD. Their safety profile is also poorly known in this 
population.  
Because of the increasing prevalence of CKD (especially mild to moderate stages) in 
patients with T2DM, there is an urgent need for a clarification of the use of glucose-lowering 
agents in this population and for the development of new agents that are efficacious and safe 
to control hyperglycemia despite impaired renal function. 
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 The reduction in kidney function is a common observation in patients with type 2 
diabetes, especially over 65 years, although this problem is frequently overlooked by the 
physician and unknown by the patient.   
 Renal function should be measured in all diabetic patients before prescribing any 
glucose-lowering agent and regularly monitored to detect worsening, especially when 
events that may potentially deteriorate renal function occur. 
 The pharmacokinetics of almost all glucose-lowering agents may be altered by renal 
impairment, thus requiring appropriate dosage adjustments according to the reduction in 
glomerular filtration rate (creatinine clearance). 
 Metformin, the first choice oral antidiabetic agent, is officially contraindicated when 
creatinine clearance is  < 60 ml/min/1,73 m², although real life data show that this drug is 
largely prescribed in patients with lower creatinine clearance without any problem and 
with potential benefits. In more recent guidelines, a dose reduction is proposed below < 
45-60 ml/min/1,73 m², and the drug must be stopped at 30 ml/min/1,73 m². 
 Most sulfonylureas are excreted by the kidneys (either parent drug or active metabolites), 
explaining why these drugs expose to a higher risk of (severe) hypoglycemia in diabetic 
patients with chronic kidney disease. DPP-4 inhibitors, whose dosage should also be 
reduced in presence of renal impairment (except linagliptin), offer clear advantages in 
this regard. 
 The efficacy and safety of GLP-1 receptor agonists and new SGLT2 inhibitors remain 
largely unknown in patients with CKD and warrant further studies before using such 
agents in this population. 
 
Figure 1 : Use of glucose-lowering medications according to the degree of renal impairment 
assessed by the glomerular filtration rate (eGFR). (*) The level of GFR may depend on the 
type of sulfonylurea (see text). 
  
Table 1 : Drug exposure (AUC) in subjects with various degrees of renal impairment (RI ; 
according to the level of creatinine clearance) compared with subjects with normal renal 
function. Results are expressed as % changes versus subjects with normal renal function or as 
geometric mean ratio (GMR) RI/normal renal function (90% confidence intervals). NA : data 
not available. 
 
 Reference Mild RI Moderate RI  Severe RI Hemodialysis
Metformin Sambol et al 
199533 NA NA NA NA 
Glibenclamide 
M1 + M2 
(active 
metabolites)  





















Glipizide Balant et al 
197373 NA NA NA NA 
Gliclazide McGavin et al 
200277 NA NA NA NA 
Repaglinide Marbury et al 
200089 NA + 19% +32% +32% 
Nateglinide Deviveni et al 
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(+71%) 
(1.52-1.93) 
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(+56%) 
(1.06-2.32) 
1.41   
(+41%) 
(1.04-1.91) 





















































(*) Model-derived point estimates for the mid-point of each renal impairment category 
(**) NA – not available without post-dose hemodialysis 
Table 2 : Clinical practice recommendations regarding the use of glucose-lowering agents in 
T2DM patients with various degrees of RI according to the level of glomerular filtration rate 
















- Metformin Increased Lactic acidosis 
≥ 60 : yes 
30-45 : caution 
(half dose) 
< 30 : stop 
No (dialysis 











≥ 60 : yes 






≥ 60 : yes 
















Yes ( few data) No data 
Glinides 
- Repaglinide No change Hypoglycemia 
(less than with 
sulfonylureas) 
Yes Yes 
- Nateglinide Modest 
change <60 : caution No 
Alpha-glucosidase inhibitors 
- Acarbose/Miglitol Increased (metabolite) Unknown 
< 60 : caution 
≥ 60 : yes No 
< 60 : caution 
Thiazolidinediones 
- Pioglitazone/ 




≥ 60 : yes 





DPP-4 inhibitors     
- Sitagliptin Increased 
Unknown 
≥ 50 : yes 
30-50 : half dose 
< 30 : quarter dose 
Caution 
- Vildagliptin Increased 
≥ 50 : yes 







≥ 50 : yes 
< 50 : half dose 
< 30 : caution 
No 
- Alogliptin Increased 
≥ 50 : yes 
< 50 : reduced 
dose 
Caution 




- Dapagliflozin Increased Unknown 
≥ 60 : yes 
< 60 : no 
No 
GLP-1 receptor agonists 
- Exenatide No change 
 
Unknown 
≥ 60 : yes 
30-60 : caution 
< 30 : no 
No 
- Liraglutide No change 
≥ 50 : yes 
< 50 : no 
No 
Insulin 
Insulin & insulin analogs Increased Hypoglycemia Yes (reduced daily dose) Yes 
 
Table 3 : Various stages of chronic kidney disease (CKD) according to the glomerular 
filtration rate estimated by the MDRD formula (eGFR) or the creatinine clearance (CLCR) 
calculated by the Cockroft-Gault formula. 
Stage Description 
eGFR  
derived from MDRD 
formula 




GFR (ml/min/1.73 m2)  
= 




GFR (ml/min) = 
(140-age) x weight 
(kg)/ plasma 
creatinine [µmol/L] 
Correction factor  
Woman : x 0.742 
Afro-American : x 
1.21 
Woman : x 1.03 





2 Mild CKD 60-89 50-80 
3 (*) Moderate CKD 30-59 30-50 




< 15 ( or dialysis) Dialysis 
 
* Stage 3 may be divided in two categories : 3a between 45 et 59 ml/min/1.73 m² and 3b 
between 30 and 44 ml/min/1.73 m².
  
Table 4 : Proposed recommendations for use of metformin based on eGFR (adapted from 





≥ 60 No renal contraindication to metformin 
Monitor renal function annually 
< 60 à ≥ 45 
Continue metformin use if well tolerated 
Increase monitoring of renal function (every 3-6 months) 
Avoid any nephrotoxic drugs 
Stop metformin in case of serious acute event and dehydration 
< 45 à ≥ 30 
Prescribe metformin with caution 
Use lower dose (e.g., 50%, or half-maximal dose) 
Closely monitor renal function (every 3 months) 
Avoid any nephrotoxic drugs 
Stop metformin in case of serious acute event and dehydration 
Do not start new patients on metformin 
< 30 
Stop metformin 
Adjust antidiabetic therapy is necessary 
Closely monitor renal function (every 6 weeks) 
 
Additional caution is required in patients at risk for acute kidney injury or with anticipated 
significant fluctuations in renal status, based on previous history, other comorbidities, or 
potentially interacting medications. 
  
Table 5 : Dose adjustments recommended when using incretin-based therapies in patients 
with various stages of renal impairment (RI) based on previous pharmacokinetics studies. 
CLCR : creatinine clearance.NR : not recommended 
 
 
RI Mild Moderate Severe ESRD 
STAGE 1-2 3 4 5 
CLCR 
ml/min 
≥ 50 ≥30 -<50 <30 Dialysis 









Vildagliptin 2 x 50 
mg/day 
1 x 50 
mg/day 
1 x 50 
mg/day 


























Exenatide 2 x 10 
µg/day 
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